Table 1 Study characteristics

No. of studies

16 (88.89%)

2 (11.11%)

18

Human Development Index [40]

 Low (< 0.550)

–

–

–

 Middle (0.550–0.699)

–

–

–

 High (0.700–0.799)

16 (88.89%)

2 (11.11%)

18

 Very high (≥ 0.800)

–

–

–

Study design

 Case control

–

1 (5.56%)

1

 Cohort

11 (61.11%)

–

11

 Cross-sectional

2 (11.11%)

–

2

 Cross-sectional/diagnostic accuracy^b

–

1 (5.56%)

1

 Nonrandomized experimental

1 (5.56%)

–

1

 Randomized controlled

2 (11.11%)

–

2

Funded

 Yes

2 (11.11%)

1 (5.56%)

3

 No

6 (33.33%)

–

6

 Not specified

8 (44.4%)^c

1 (5.56%)

9

No. of centers

 Single

15 (83.33%)

2 (11.11%)

17

 Multiple

1 (5.56%)^d

-

1

Patient population

 Oncology institute

1 (5.56%)^c

–

1

University

15 (83.33%)

1 (5.56%)

16

 Not specified (in urban area)

–

1 (5.56%)^d

1

Year of study publication

 2010–2013 (included)

5 (27.7%)

–

5

 2015–2018

4 (22.2%)

–

4

 2019–2021

7(38.9%)

2 (11.11%)

9

Conflict of interest

 None

14 (87.5%)^c

1 (5.56%)

16

 Not specified

2 (11.11%)

1 (5.56%)

3

Funded

 Yes

2 (11.11%)

1 (5.56%)

3

 No

6 (33.3%)

–

6

Not specified

8 (44.4%)^c

1 (5.56%)

9

Histology (%)^f

 Endometroid adenocarcinoma

12 (66.67%)

1 (5.56%)

12

 Serous/papillary serous carcinoma

6 (33.3%)^c

–

6

 Clear cell carcinoma

2 (11.11%)

–

2

 Carcinosarcoma

1 (5.56%)^c

–

1

 Uterine sarcoma

–

–

0

 Unknown

2 (11.11%)

1 (5.56%)

3

Mean age at diagnosis (years)

 < 60

8 (44.4%)

–

8

 ≥ 60

4 (22.2%)

1 (5.56%)

5

 Unknown

4 (22.2%)

1 (5.56%)

5